Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008

Preventive Medicine

Volumn 52, Issue 5, 2011, Pages 398-400

  Taylor, La'Shan D ^a,b   Hariri, Susan ^a   Sternberg, Maya ^c   Dunne, Eileen F ^a   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

Human papillomavirus vaccine; National Health and Nutrition Examination Survey; Vaccine coverage

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; HEALTH SURVEY; HUMAN; INSURANCE; NUTRITION; PRIORITY JOURNAL; SCHOOL CHILD; SEXUAL BEHAVIOR; UNITED STATES;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; NUTRITION SURVEYS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; YOUNG ADULT;

EID: 79954583896     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2010.11.006     Document Type: Article

References (15)

1. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR 2008, 35(57):961-966. Centers for Disease Control and Prevention.
2. Centers for Disease Control and Prevention FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010 May 28, 59(20):626-629.
3. Chao C., Velicer C., Slezak J.M., et al. Correlates of human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am. J. Epidemiol. 2010, 171(3):357-367.
4. Conroy K., Rosenthal S.L., Zimet G.D., et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J. Womens Health 2009, 18(10):1679-1686.
5. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819.
6. Daley M.F., Crane L.A., Markowitz L.E., et al. Human papillomavirus vaccination practices: a survey of U.S. physicians 18months after licensure. Pediatrics 2010, 126(3):425-433.
7. Garland S.M., Steben M., Sings H.L., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis. 2009, 199(6):805-814.
8. Jain N., Euler G.L., Shefer A., et al. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev. Med. 2009, 48:426-431.
9. Kahn J., Zimet G., Bernstein M., et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J. Adolesc. Health 2005, 37:502-510.
10. Kapoor S. The HPV vaccine and behavioral disinhibition. J. Adolesc. Health. 2008, 42:105.
11. National Center for Health Statistics (NCHS) NHANES Analytic Guidelines: September 2006. Accessed November 5, 2009. http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf.
12. National Center for Health Statistics (NCHS) NHANES 2007-2008 documentation. Accessed November 5, 2009. http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/nhanes07_08.htm.
13. Schiller, J.S. and Euler, G.L. 2009. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. National Center for Health Statistics. Accessed November 18, 2009. http://www.cdc.gov/nchs/data/hestat/vaccine_coverage.pdf.
14. Shefer A., Markowitz L., Deeks S., et al. Early experiences with human papillomavirus vaccine introduction in the United States, Canada, and Australia. Vaccine 2008, 26S:K68-K75.
15. Winer R.L., Lee S.K., Hughes J.P., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 2003, 57:218-226.